Your browser doesn't support javascript.
loading
Improved Side Effect Profile of Alternate-Day Dosing of Lenalidomide.
Lawal, Ridwan A; Banjoko, Oluwole; Ndulue, Chukwunonso; Adebeshin, Sodiq T; Sharif, Arsalan; Ighodaro, Osasumwen E; Olusoji, Rahman; Odusanya, Bilikisu; El-Hamdi, Nadia S.
Afiliación
  • Lawal RA; Internal Medicine, College of Medicine, University of Lagos, Lagos, NGA.
  • Banjoko O; Internal Medicine, Lagos State University Teaching Hospital, Lagos, NGA.
  • Ndulue C; Internal Medicine, College of Medicine, University of Lagos, Lagos, NGA.
  • Adebeshin ST; Internal Medicine, University of Lagos, Lagos, NGA.
  • Sharif A; Medicine, Tbilisi State Medical University, Tbilisi, GEO.
  • Ighodaro OE; Internal Medicine, Afe Babalola University, Ado Ekiti, NGA.
  • Olusoji R; Internal Medicine, Columbia University at Harlem Hospital Center, New York, USA.
  • Odusanya B; Pediatrics, Olabisi Onabanjo University, Sagamu, NGA.
  • El-Hamdi NS; Internal Medicine, Hospital Corporation of America (HCA) Houston Healthcare Kingwood, University of Houston College of Medicine (UHCOM), Texas, USA.
Cureus ; 16(3): e55317, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38559519
ABSTRACT
Myelodysplastic syndrome (MDS) is a heterogeneous hematological condition associated with cytopenia, inadequate blood cell synthesis, and the risk of developing acute myeloid leukemia (AML). Patients are divided into risk groups according to the International Prognostic Scoring System (IPSS) to help direct therapy. Allogeneic stem cell transplantation, despite its limitations, is curative. Medical management, such as the use of lenalidomide, has potential benefits but can cause adverse effects that require dose regimen modification. Lenalidomide is approved for low-risk MDS with 5q deletion (5q- MDS). In this case study, a 79-year-old woman with 5q- MDS was switched from a daily regimen to an alternate-day lenalidomide dose schedule to achieve complete remission with fewer adverse effects. The management of hematological toxicity and the mechanisms of action of lenalidomide are discussed. We recommend individualized treatment strategies and additional research to improve MDS management.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos